Scheutz F
Int J Oral Surg. 1985 Dec;14(6):459-65. doi: 10.1016/s0300-9785(85)80050-8.
The aim of the study was to investigate the prevalence of previous clinical hepatitis B virus (HBV) infection and the prevalence of HBV markers in Danish oral surgeons, to estimate the annual HBV infection rate, and to assess whether the use of hepatitis B vaccine is to be recommended for this group. The total study population comprised 40 individuals occupied with oral surgery. A questionnaire and a request for a blood sample were sent to all dentists employed at the Danish hospitals and the departments of oral surgery at the 2 dental colleges. 36 (90%) answered a questionnaire, whereas only 27 (67.5%) had a blood sample taken for analysis of hepatitis surface antigen (HBsAg), antibody to HBsAg (anti-HBs), antibody to hepatitis core antigen (anti-HBcAg), antibody to hepatitis A virus (anti-HAV), and serumtransaminases. One had been clinically ill from HBV infection and was positive for anti-HBs. The prevalence rate was thus 3.7% (95% confidence limits: 0.1%-19.0%) and the annual attack rate was 0.3%. The prevalence was not higher than among Danish dentists in general, and they are not considered a high-risk group in Denmark. Even with due statistical consideration to the present small sample, Danish oral surgeons do not seem to belong to a high-risk group like other surgeons in different medical specialities. It is concluded that the use of a hepatitis B vaccine is not recommended at present for this group of dentists.
该研究的目的是调查丹麦口腔外科医生既往临床乙肝病毒(HBV)感染的患病率及HBV标志物的流行情况,估计年度HBV感染率,并评估是否建议该群体使用乙肝疫苗。研究总人群包括40名从事口腔外科工作的人员。向丹麦各医院的所有牙医以及2所牙科学院的口腔外科科室发送了问卷和血液样本采集请求。36人(90%)回复了问卷,而只有27人(67.5%)采集了血样,用于检测乙肝表面抗原(HBsAg)、抗HBsAg抗体(抗-HBs)、抗乙肝核心抗原抗体(抗-HBcAg)、抗甲型肝炎病毒抗体(抗-HAV)和血清转氨酶。有1人曾患临床HBV感染且抗-HBs呈阳性。因此,患病率为3.7%(95%置信区间:0.1%-19.0%),年度发病率为0.3%。该患病率并不高于丹麦普通牙医,在丹麦他们不被视为高危人群。即使考虑到目前样本量较小的统计学因素,丹麦口腔外科医生似乎也不像其他医学专科的外科医生那样属于高危人群。结论是,目前不建议该组牙医使用乙肝疫苗。